The new office is expected to strengthen PPD’s presence in Eastern Europe beyond Russia and Ukraine, countries where the company is expanding through its pending acquisition of InnoPharm. PPD has targeted Eastern Europe, an important, high-growth market for clinical trials, for its expansion.
Fred Eshelman, CEO of PPD, said: “Eastern Europe offers recruitment opportunities and quality investigators, and our Istanbul office is an important part of our strategic growth in this region. We plan to continue to expand in areas where there is high demand for our global experience and therapeutic expertise.”